Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), today announced it will participate at the EUROGIN (European Research Organisation on Genital Infection and Neoplasia) 2016 Congress held from June 15 to 18, 2016 at the Salzburg, Austria, Convention Center, where the Company will present the 12 month interim results of the European phase 2 trial of GTL001 as well as provide further preclinical proof of concept data for GTL002.
The EUROGIN congress, which gathers scientists, clinicians and gynecologists, aims at providing an overview of current scientific advances in the field of cervical cancer and other diseases related to Human Papillomavirus (HPV) infection.
Presentations featuring GTL001 and GTL002, Genticel's candidates against HPV infections, will take place on Friday, June 17, as part of the scientific sessions on immunology and immunotherapeutics SSim) of the main program.
Session SSim 02-06 (GTL002)
June 17, 2016 | 16.15 – 17.45 | Europa Hall | Read the abstract
Session SSim 03-04 (GTL001)
June 17, 2016 | 17.45 – 19.15 | Europa Hall | Read the abstract
Genticel is also present on the exhibitor floor at booth 9.
About Eurogin 2016
The EUROGIN 2016 Congress aims at developing a full review of current scientific developments in the field of cancer and human papillomavirus related diseases, raising the public health profile and increasing the need for responsible health services in this area. The event endeavours to translate scientific and evidence-based research into clinical practice while highlighting the following aspects:
- Recent advances and updated scientific insights in HPV screening, testing and management
- The impact of HPV and associated cancers on public health
- Strategies to prevent and treat HPV related diseases
- Exchanging information on early detection, new diagnostic and therapeutic procedures and prevention strategies including screening and HPV vaccination
Speakers include international leaders from academic, government and private organizations, representatives of medical and scientific societies, as well as women's health associations.
More information at www.eurogin.com
 Please refer to the press releases issued by the Company on January 27 and April 20, 2016.
Aiming to solve a public health issue.
Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and 275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early stage with GTL001, its first-in-class immunotherapeutic candidate. GTL001 is more than halfway through a 24-month proof of concept Phase 2 trial in Europe.
Offering a promising technological platform.
Genticel's versatile platform, Vaxiclase, is ideally suited for the development of immunotherapies against multiple infectious or cancerous diseases. Genticel's second candidate, GTL002, is a multivalent HPV immunotherapeutic candidate designed with Vaxiclase. It targets the six most relevant HPV types in terms of global epidemiology and is currently in preclinical development.
Focusing on value creation.
Respectively, the peak sales potentials of GTL001 and GTL002 are estimated at over €1 billion and €2 billion per year. In addtion to this attractive HPV product pipeline, Genticel's versatile technological platform, Vaxiclase, has already generated significant interest in the pharmaceutical industry, as illustrated by the partnership agreement signed in 2015 with the Serum Institute of India Ltd. (SIIL), the world's largest producer of vaccine doses. This partnership could generate up to $57 million in revenues for Genticel, before royalties on sales. It will enable SIIL to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough.
More information at www.genticel.com
Forward Looking Statement
This press release contains forward-looking statements that are not promises or guarantees and involve substantial risks and uncertainties. The Company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French “Autorité des Marchés Financiers”, including in the Company's Annual Report for the year ended December 31, 2015 and future filings and reports by the Company which are available on the Company's website.. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Genticel undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.
Investor Relations & Corporate Communications
+ 33 6 33 34 37 30
|Life Sci Advisors
+1 212 915 2578
Caroline Carmagnol et
+33 6 64 18 99 59 / +33 6 47 38 90 04